Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study

Journal of the American College of Cardiology

Volumn 44, Issue 7, 2004, Pages 1386-1392

  Waksman, Ron ^a,c   Ajani, Andrew E ^b   Pichard, Augusto D ^a   Torguson, Rebecca ^a   Pinnow, Ellen ^a   Canos, Daniel ^a   Satler, Lowell F ^a   Kent, Kenneth M ^a   Kuchulakanti, Pramod ^a   Pappas, Chrysoula ^a   Gambone, Louise ^a   Weissman, Neil ^a   Abbott, Maureen C ^a   Lindsay, Joseph ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MONASH UNIVERSITY   (Australia)

^c Suite 4B 1 Washington DC 20010 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIARRHEA; DRUG COST; DRUG ELUTING STENT; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; INTRAVASCULAR ULTRASOUND; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; RASH; RESTENOSIS; VOMITING;

ADMINISTRATION, ORAL; AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SIROLIMUS; STENTS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 4644241907     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.069     Document Type: Article

References (27)

1. P.A. Lemos, C. Lee, M Degertekin Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry J Am Coll Cardiol 41 2003 2093 2099
2. J.E. Sousa, M.A. Costa, A.G Sousa Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries Circulation 107 2003 381 383
3. M. Degertekin, E. Regar, K Tanabe Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience J Am Coll Cardiol 41 2003 184 189
4. RAVEL Study Group E. Regar, P.W. Serruys, C., et al Bode Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size Circulation 106 2002 1949 1956
5. M. Degertekin, P.W. Serruys, D.P Foley Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up Circulation 106 2002 1610 1613
6. RAVEL Study Group P.W. Serruys, M. Degertekin, K., et al Tanabe Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial Circulation 106 2002 798 803
7. RAVEL Study Group M.C. Morice, P.W. Serruys, J.E., et al Sousa Randomized study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
8. J.W. Moses, M.B. Leon, J.J Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
9. R. Virmani, F. Liistro, G Stankovic Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans Circulation 106 2002 2649 2651
10. F. Liistro, G. Stankovic, C Di Mario First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome Circulation 105 2002 1883 1886
11. C.G. Groth, L. Backman, J.M Morales Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine: Sirolimus European Renal Transplant study group Transplantation 67 1999 1036 1042
12. D.S. Collier, R. Calne, S Thiru Rapamycin in experimental renal allografts in dogs and pigs Transplant Proc 22 1990 1674 1675
13. D.K. Granger, J.W. Cromwell, S.C Chen Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy Transplantation 59 1995 183 186
14. P.S. Almond, A. Moss, R Nakhleh Rapamycin in a porcine renal transplant model Ann NY Acad Sci 685 1993 121 122
15. R.E. Morris, B.M. Meiser, J Wu Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions Transplant Proc 23 1991 521 524
16. D.S. Collier, R.Y. Calne, S.G Pollard Rapamycin in experimental renal allografts in primates Transplant Proc 23 1991 2246 2247
17. B.D. Kahan, M.G. Murgia, J Slaton Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation Ther Drug Monit 17 1995 672 675
18. R. Gallo, A. Padurean, T Jayaraman Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle Circulation 99 1999 2164 2170
19. A. Farb, M. John, E Acampado Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379 2384
20. J.E. Sousa, M.A. Costa, A.C Abizaid Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up Circulation 104 2001 2007 2011
21. S.O. Marx, T. Jayaraman, L.O Go Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells Circ Res 76 1995 412 417
22. M. Poon, S.O. Marx, R Gallo Rapamycin inhibits vascular smooth muscle cell migration J Clin Invest 98 1996 2277 2283
23. P.S. Brara, M. Moussavian, M.A Grise Pilot trial of oral rapamycin for recalcitrant restenosis Circulation 107 2003 1722 1724
24. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110:790-5.
25. A.E. Rodríguez, M.R. Alemparte, C.F Vigo Pilot study of Oral Rapamycin to Prevent Restenosis in Patients Undergoing Coronary Stent Therapy: Argentina single-center study (ORAR trial) J Invasive Cardiol 15 2003 581 584
26. R.S. Poston, M. Billingham, E.G Hoyt Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model Circulation 100 1999 67 74
27. D. Mancini, S. Pinney, D Burkhoff Use of rapamycin slows progression of cardiac transplantation vasculopathy Circulation 108 2003 48 53